Edotreotide

Edotreotide (USAN, also known as (DOTA0-Phe1-Tyr3) octreotide, DOTA-TOC, DOTATOC) is a substance which, when bound to various radionuclides, is used in the treatment and diagnosis of certain types of cancer.A phase I clinical trial of yttrium-90 labelled edotreotide concluded in 2011,[4] aiming to investigated effects in young cancer patients (up to 25 years of age).[5] A phase II trial for the use of 90Y DOTA-TOC for patients with metastatic carcinoid, where octreotide treatment was no longer effective, also reported results in 2010.[6] Lutetium-177 labelled edotreotide (177Lu-DOTA-TOC), with the trade name Solucin, is the subject of a phase 3 clinical trial for treatment of GEP-NETs.[7][8] It was granted orphan drug designation by the European Medicines Agency in 2014.
Yttrium-90 labeled edotreotide
IUPAC nameCAS NumberChEMBLChemSpiderDrugBankPubChemCompTox DashboardSMILESChemical formulaMolar massLicense dataLegal statusstandard stateoctreotideradionuclidespeptide receptor radionuclide therapyphase I clinical trialyttrium-90neuroblastomabrain tumoursgastrointestinal cancerphase II trialmetastaticcarcinoidLutetium-177trade namephase 3 clinical trialGEP-NETsorphan drug designationEuropean Medicines AgencyDOTA-TATEGH/IGF-1 axissignalingmodulatorsGH(somatotropin)Bovine somatotropinGrowth hormoneHuman placental lactogenLonapegsomatropinPlacental growth hormone (growth hormone variant)SomapacitanSomatotropinSomatremSomatrogon (MOD-4023; hGH-CTP)PegvisomantGHIH(somatostatin)LanreotideOctreotatePasireotideSomatostatin (GHIH)VapreotideGHRH(somatocrinin)CJC-1295Modified GRF (1-29)SermorelinSomatorelinTesamorelinGHS(ghrelin)Examorelin (hexarelin)GhrelinGHRP-6IpamorelinLenomorelinPralmorelin (GHRP-2)RelamorelinTabimorelinUlimorelinAdenosineAnamorelinCapromorelinIbutamoren (MK-677)MacimorelinSM-130686IGF-1(somatomedin)pharmacology